Previous 10 | Next 10 |
home / stock / ncna / ncna articles
NuCana Plc (NASDAQ:NCNA) shares are trading higher Wednesday after the company was granted a U.S. Patent for phosphoramidate derivatives for use in...
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 150 points on Wednesday. The Dow traded up 0.42% to 39,170.63 wh...
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 50 points on Wednesday. Following the market opening Wednesday, the...
EDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Office...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares surged 79.5% to $5.08 in pre-market trading after falling around 7% on Monday. SciSparc recently rega...
Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed ...
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-l...
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced four presentations at the upcoming AACR-NCI-EOR...
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 38.7% to $0.1421 in pre-market trading after gaining 10% on Thursday. MSP Recove...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...